HOME >> BIOLOGY >> NEWS
New study ties moderate beer drinking to lower heart attack risk

A beer a day may help keep heart attacks away, according to a group of Israeli researchers. In preliminary clinical studies of a group of men with coronary artery disease, the researchers showed that drinking one beer (12 ounces) a day for a month produced changes in blood chemistry that are associated with a reduced risk of heart attack.

Their study adds to growing evidence that moderate alcohol consumption may reduce the risk of heart disease, the number one killer in the United States. Their findings are scheduled to appear in the Jan. 29 print edition of the Journal of Agricultural and Food Chemistry, a peer-reviewed publication of the American Chemical Society, the world's largest scientific society.

Heart-healthy changes observed in the blood of the test participants following beer-drinking include decreased cholesterol levels, increased antioxidants and reduced levels of fibrinogen, a clot-producing protein, according to the researchers.

The study also showed, for the first time, that drinking alcoholic beverages causes structural changes in fibrinogen that make the clotting protein less active, says lead investigator Shela Gorinstein, Ph.D., a researcher with The Hebrew University of Jerusalem in Israel. Characterizing these structural changes of fibrinogen may one day serve as a new diagnostic indicator of heart attack risk, along with known risk indicators such as blood cholesterol and antioxidant levels, she says. Further studies are needed.

Forty-eight (48) men, ages 46-72, with coronary artery disease were divided evenly into two groups. Individuals in one group drank the equivalent of 12 ounces (one standard can or bottle) of beer a day for 30 consecutive days, while the others drank mineral water. Both groups ate a similar diet, rich in fruits and vegetables, during this period.

In 21 of the 24 patients in the beer-drinking group, the researchers found positive changes in blood chemicals that are assoc
'"/>

Contact: Beverly Hassell
b_hassell@acs.org
202-872-4065
American Chemical Society
30-Dec-2002


Page: 1 2 3

Related biology news :

1. Student science contest participation influences study, career choices, alumni say
2. New study shows hope for treating inhalant abuse
3. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
4. Cigarette smoke causes breaks in DNA and defects to a cells chromosomes, Pitt study finds
5. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
6. Phase II trials of second-generation antisense cancer drug planned following successful early study
7. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
8. Indiana University, EPA to study airborne PCBs
9. K-State, other universities to study how climate affects plant evolution
10. USC study links historical increases in life span to lower childhood exposure to infection
11. Washington University in St. Louis leads group studying aging process

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New study ties moderate beer drinking lower heart attack risk

(Date:10/22/2014)... Medicine® scientists helps explain how bipolar disorder affects the ... therapies to treat the mental illness. , Scientists ... method recognized with the 2014 Nobel Prize in ... from mice with bipolar-like behaviors. In the synapses (where ... structures with concentrated levels of ANK3 -- the gene ...
(Date:10/22/2014)... , Oct. 20, 2014  Leading identity analyst firm ... half of the world,s population will have a chip-based ... Europe . Asia , ... market accounting for more than 60% of all National ... Acuity,s report  -- "The Global National eID ...
(Date:10/19/2014)... in India over the last 30 years contributed ... growth during that time, according to a new ... Change ., "Energy access is fundamental to development: ... including education, communication, and health," says IIASA researcher ... increased energy access is widely agreed to be ...
Breaking Biology News(10 mins):Bipolar disorder discovery at the nano level 2Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Improved electricity access has little impact on climate change 2
(Date:10/25/2014)... , October 24, 2014 ... Corporation (NASDAQ: CYTR ), Vertex Pharmaceuticals Inc. ... ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... Thursday, October 23, 2014, ended on a positive note ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis ... specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today ... to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., ... for the treatment of diabetic gastroparesis and other GI ... successful Phase 2 trial of relamorelin for the treatment ...
(Date:10/22/2014)... WriteResult, LLC – a premier provider of ... a team of researchers from Yale University’s School of ... to provide electronic questionnaire data collection through use of ... in May, aims to evaluate the impact of a ... and participation in urban agriculture to impact their consumption ...
(Date:10/22/2014)... ROCKVILLE, Md. , Oct. 22, 2014   ... company developing novel pathogen-specific therapies for serious infections and ... Office has issued a Notice of Allowance for a ... product in its C. difficile program, SYN-004. This ... to SYN-004 in the U.S. and adds to the ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
Cached News: